middle.news
Vertex expands beyond cystic fibrosis as revenue guidance rises
8:05am on Tuesday 3rd of November, 2026 AEDT
•
Biotechnology
Read Story
Vertex expands beyond cystic fibrosis as revenue guidance rises
8:05am on Tuesday 3rd of November, 2026 AEDT
Key Points
Third-quarter revenue rose 12% to US$3.44 billion
Full-year revenue guidance lifted to US$13.15 billion-US$13.25 billion
GAAP net income fell to US$653.6 million after Crinetics-related costs
CASGEVY revenue nearly sextupled year on year to US$99.2 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
OPEN ARTICLE